Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYN-AR-B
- Development stage
- Unknown
- Lead developer
- FUTRUE
- Modality
- Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
SYN-AR-B is an investigational oral botanical drug candidate developed by FUTRUE R&S 2 GmbH for the treatment of allergic rhinoconjunctivitis caused by grass pollen. It is one of three experimental formulations (alongside SYN-AR-A and SYN-AR-C) derived from a proprietary extract of *Astragalus membranaceus* root. The drug is designed to function as an immunomodulator, aiming to alleviate allergy symptoms by balancing Th1 and Th2 immune responses and potentially reducing the production of allergen-specific Immunoglobulin E (IgE) and pro-inflammatory cytokines. SYN-AR-B has been evaluated in randomized, placebo-controlled Phase 2 clinical trials in Germany to assess its efficacy in reducing the Total Nasal Symptom Score (TNSS) and Total Ocular Symptom Score (TOSS) in patients with seasonal grass pollen exposure.
- Other names
- SYN-AR formulation B
02
Targets
IL-4 (Interleukin 4)IgE (Immunoglobulin E)IFNG (Interferon gamma)
Beyond the preview
Go deeper on SYN-AR-B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYN-AR-B.